Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Androcur Non-interventional Study Among Patients With Carcinoma of the Prostate (ANES)

This study has been terminated.
Information provided by:
Bayer Identifier:
First received: June 9, 2009
Last updated: October 30, 2012
Last verified: October 2012

Cyproterone acetate (CPA) is a steroidal antiandrogen which has affinity with progesterone and with glucocorticoid receptors. Cyproterone acetate is long-term proven effective treatment of inoperable carcinoma of the prostate.

Sexual functions remain very important in men with prostate cancer. However sexual functions are deteriorating fast with course of the disease. The influence of CPA on sexual functions remains controversial. IIEF-5 erectile dysfunction questionnaire is currently widely used validated simple scoring system for diagnosing of erectile dysfunction and belongs to most used systems in Czech Republic. At present there are no data on CPA influence on IIEF-5 scored erectile dysfunction within the use of its indication in prostate cancer.

Condition Intervention
Prostate Cancer
Drug: Cyproterone Acetate (Androcur, BAY94-8367)

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Prospective Observational Non-interventional Study of Correlation of Treatment With Androcur, Disease Stage, Testosterone Level, Age With Sexual Function and Erectile Dysfunction (Measured by IIEF-5 Validated Questionnaire)

Resource links provided by NLM:

Further study details as provided by Bayer:

Primary Outcome Measures:
  • Correlation of treatment with Androcur (concomitant treatment), disease stage, testosterone level, age with erectile dysfunction (measured by IIEF-5 validated questionnaire) [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Correlation of PSA level and erectile dysfunction [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Sexual activity of Czech patients with inoperable prostate cancer [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Biospecimen Retention:   None Retained


Enrollment: 194
Study Start Date: August 2009
Study Completion Date: August 2011
Groups/Cohorts Assigned Interventions
Group 1 Drug: Cyproterone Acetate (Androcur, BAY94-8367)
Patients in regular clinical practice receiving Androcur according to local drug information


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Random sample of cancer patients visiting oncologist or urologist ambulance who are suitable for standard Cyproterone treatment.


Inclusion Criteria:

  • Males > 18 years previously untreated with Androcur.
  • No contraindication to Androcur.

Exclusion Criteria:

  • Liver diseases, malignant liver tumours and wasting diseases (except for carcinoma of the prostate). A history of or existing thrombosis or embolism. Severe chronic depression. Hypersensitivity to cyproterone. Cyproterone acetate in previous therapy.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00919022

Czech Republic
Many Locations, Czech Republic
Sponsors and Collaborators
Study Director: Bayer Study Director Bayer
  More Information

Additional Information:
No publications provided

Responsible Party: Medical Director, Bayer HealthCare AG Identifier: NCT00919022     History of Changes
Other Study ID Numbers: 14556, AC0910CZ
Study First Received: June 9, 2009
Last Updated: October 30, 2012
Health Authority: Czech Republic: State Institute for Drug Control

Keywords provided by Bayer:
Inoperable Prostate Cancer
Erectile Dysfunction processed this record on March 03, 2015